allele_iedb stringclasses 37
values | allele stringclasses 37
values | peptide stringlengths 7 15 | peptide_length int64 7 15 | measurement_type stringclasses 2
values | measurement_value float64 0 14.3M | measurement_units stringclasses 1
value | assay_method stringclasses 6
values | assay_response stringclasses 2
values | pubmed_id float64 7.51M 37.8M ⌀ | parent_protein stringlengths 3 188 ⌀ | protein_accession stringlengths 6 14 | source_organism stringclasses 849
values | assay_pdb_id float64 | flagged bool 2
classes | has_structures bool 1
class | num_pdbs int64 22 25 | rosetta_best_score float64 -633.25 1.04 | rosetta_mean_score float64 -620.04 44 | pdb_dir stringlengths 24 32 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLA-A_02_01 | A*02:01 | KVKIPVAIKTS | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -534.139 | -475.6067 | structures/A0201/KVKIPVAIKTS |
HLA-A_02_01 | A*02:01 | VKIPVAIKT | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -554.365 | -510.7659 | structures/A0201/VKIPVAIKT |
HLA-A_02_01 | A*02:01 | VKIPVAIKTS | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -575.983 | -491.9378 | structures/A0201/VKIPVAIKTS |
HLA-A_02_01 | A*02:01 | VKIPVAIKTSP | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -527.405 | -497.9931 | structures/A0201/VKIPVAIKTSP |
HLA-A_02_01 | A*02:01 | KIPVAIKT | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -558.188 | -491.5412 | structures/A0201/KIPVAIKT |
HLA-A_02_01 | A*02:01 | KIPVAIKTS | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -565.941 | -537.4793 | structures/A0201/KIPVAIKTS |
HLA-A_02_01 | A*02:01 | KIPVAIKTSP | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -557.613 | -533.4404 | structures/A0201/KIPVAIKTSP |
HLA-A_02_01 | A*02:01 | KIPVAIKTSPK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -561.239 | -526.9828 | structures/A0201/KIPVAIKTSPK |
HLA-A_02_01 | A*02:01 | IPVAIKTS | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -559.823 | -521.7851 | structures/A0201/IPVAIKTS |
HLA-A_02_01 | A*02:01 | IPVAIKTSP | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -556.938 | -529.9176 | structures/A0201/IPVAIKTSP |
HLA-A_02_01 | A*02:01 | IPVAIKTSPK | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -521.332 | -491.8165 | structures/A0201/IPVAIKTSPK |
HLA-A_02_01 | A*02:01 | IPVAIKTSPKA | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -545.372 | -521.1137 | structures/A0201/IPVAIKTSPKA |
HLA-A_02_01 | A*02:01 | PVAIKTSP | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -551.858 | -537.3208 | structures/A0201/PVAIKTSP |
HLA-A_02_01 | A*02:01 | PVAIKTSPK | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -559.27 | -525.958 | structures/A0201/PVAIKTSPK |
HLA-A_02_01 | A*02:01 | PVAIKTSPKA | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -561.212 | -502.5911 | structures/A0201/PVAIKTSPKA |
HLA-A_02_01 | A*02:01 | PVAIKTSPKAN | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -562.726 | -534.6424 | structures/A0201/PVAIKTSPKAN |
HLA-A_02_01 | A*02:01 | VAIKTSPK | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -547.032 | -508.1932 | structures/A0201/VAIKTSPK |
HLA-A_02_01 | A*02:01 | VAIKTSPKA | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -571.058 | -553.1011 | structures/A0201/VAIKTSPKA |
HLA-A_02_01 | A*02:01 | VAIKTSPKAN | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -556.609 | -518.0304 | structures/A0201/VAIKTSPKAN |
HLA-A_02_01 | A*02:01 | VAIKTSPKANK | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -576.383 | -543.3018 | structures/A0201/VAIKTSPKANK |
HLA-A_02_01 | A*02:01 | AIKTSPKA | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -559.395 | -538.1658 | structures/A0201/AIKTSPKA |
HLA-A_02_01 | A*02:01 | AIKTSPKAN | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -561.231 | -520.5306 | structures/A0201/AIKTSPKAN |
HLA-A_02_01 | A*02:01 | AIKTSPKANK | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -560.337 | -509.7199 | structures/A0201/AIKTSPKANK |
HLA-A_02_01 | A*02:01 | AIKTSPKANKE | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -544.4 | -520.8966 | structures/A0201/AIKTSPKANKE |
HLA-A_02_01 | A*02:01 | IKTSPKAN | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -544.266 | -510.6361 | structures/A0201/IKTSPKAN |
HLA-A_02_01 | A*02:01 | IKTSPKANK | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -543.902 | -489.9057 | structures/A0201/IKTSPKANK |
HLA-A_02_01 | A*02:01 | IKTSPKANKE | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -532.576 | -493.2929 | structures/A0201/IKTSPKANKE |
HLA-A_02_01 | A*02:01 | IKTSPKANKEI | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -537.398 | -491.2601 | structures/A0201/IKTSPKANKEI |
HLA-A_02_01 | A*02:01 | KTSPKANK | 8 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -547.608 | -527.0221 | structures/A0201/KTSPKANK |
HLA-A_02_01 | A*02:01 | KTSPKANKE | 9 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -534.774 | -469.2872 | structures/A0201/KTSPKANKE |
HLA-A_02_01 | A*02:01 | KTSPKANKEI | 10 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -562.484 | -497.239 | structures/A0201/KTSPKANKEI |
HLA-A_02_01 | A*02:01 | KTSPKANKEIL | 11 | IC50 | 20,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -570.259 | -550.0228 | structures/A0201/KTSPKANKEIL |
HLA-A_02_01 | A*02:01 | HVKITDFGL | 9 | IC50 | 50,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -553.474 | -515.089 | structures/A0201/HVKITDFGL |
HLA-A_02_01 | A*02:01 | FGLAKLLGA | 9 | IC50 | 106.71 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -540.102 | -502.8467 | structures/A0201/FGLAKLLGA |
HLA-A_02_01 | A*02:01 | GLAKLLGAEEK | 11 | IC50 | 50,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -572.646 | -535.6235 | structures/A0201/GLAKLLGAEEK |
HLA-A_02_01 | A*02:01 | LAKLLGAEEK | 10 | IC50 | 50,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | AFK93477.1 | Homo sapiens | null | false | true | 25 | -570.842 | -550.1658 | structures/A0201/LAKLLGAEEK |
HLA-A_02_01 | A*02:01 | VLNGNDNTI | 9 | IC50 | 7,306 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Erythrocyte binding antigen-175 | Q8IBE8.2 | Plasmodium falciparum | null | false | true | 25 | -546.358 | -506.3406 | structures/A0201/VLNGNDNTI |
HLA-A_02_01 | A*02:01 | SLIKQNKYV | 9 | IC50 | 29,876 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Erythrocyte binding antigen-175 | Q8IBE8.2 | Plasmodium falciparum | null | false | true | 25 | -562.299 | -518.7414 | structures/A0201/SLIKQNKYV |
HLA-A_02_01 | A*02:01 | SVLNGNDNTI | 10 | IC50 | 640,079 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Erythrocyte binding antigen-175 | Q8IBE8.2 | Plasmodium falciparum | null | false | true | 25 | -566.132 | -486.9026 | structures/A0201/SVLNGNDNTI |
HLA-A_02_01 | A*02:01 | FLPTGAFKA | 9 | IC50 | 1,391 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -575.522 | -509.8383 | structures/A0201/FLPTGAFKA |
HLA-A_02_01 | A*02:01 | NLFSSIEIV | 9 | IC50 | 1,555 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -570.149 | -512.431 | structures/A0201/NLFSSIEIV |
HLA-A_02_01 | A*02:01 | CLINNSSYI | 9 | IC50 | 3,818 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -557.062 | -526.3207 | structures/A0201/CLINNSSYI |
HLA-A_02_01 | A*02:01 | SMIKSAFLPT | 10 | IC50 | 12,520 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -574.964 | -548.5294 | structures/A0201/SMIKSAFLPT |
HLA-A_02_01 | A*02:01 | YMGNPWTEYM | 10 | IC50 | 21,393 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -537.556 | -446.4594 | structures/A0201/YMGNPWTEYM |
HLA-A_02_01 | A*02:01 | AVLATILMV | 9 | IC50 | 23,635 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -556.883 | -529.057 | structures/A0201/AVLATILMV |
HLA-A_02_01 | A*02:01 | FISDDKDSL | 9 | IC50 | 335,616 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -586.137 | -572.1366 | structures/A0201/FISDDKDSL |
HLA-A_02_01 | A*02:01 | KRASHTTPV | 9 | IC50 | 100,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Apical membrane antigen 1 | Q7KQK5.1 | Plasmodium falciparum | null | false | true | 25 | -549.46 | -517.6225 | structures/A0201/KRASHTTPV |
HLA-A_02_01 | A*02:01 | FQYNDDASI | 9 | IC50 | 275.4 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Rh5-interacting protein | O97302.1 | Plasmodium falciparum | null | false | true | 25 | -553.104 | -501.309 | structures/A0201/FQYNDDASI |
HLA-A_02_01 | A*02:01 | YLNKYVYTI | 9 | IC50 | 342.1 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Rh5-interacting protein | O97302.1 | Plasmodium falciparum | null | false | true | 25 | -587.233 | -516.8486 | structures/A0201/YLNKYVYTI |
HLA-A_02_01 | A*02:01 | YIYNQIIWKI | 10 | IC50 | 1,950 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Rh5-interacting protein | O97302.1 | Plasmodium falciparum | null | false | true | 25 | -553.378 | -475.8042 | structures/A0201/YIYNQIIWKI |
HLA-A_02_01 | A*02:01 | FVLENGVCI | 9 | IC50 | 4,174 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Rh5-interacting protein | O97302.1 | Plasmodium falciparum | null | false | true | 25 | -562.35 | -515.584 | structures/A0201/FVLENGVCI |
HLA-A_02_01 | A*02:01 | KLTFSLDHRV | 10 | IC50 | 8,876 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Rh5-interacting protein | O97302.1 | Plasmodium falciparum | null | false | true | 25 | -558.617 | -480.9106 | structures/A0201/KLTFSLDHRV |
HLA-A_02_01 | A*02:01 | KLGVQYFFL | 9 | IC50 | 805.2 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Cysteine-rich protective antigen | Q8IFM8.1 | Plasmodium falciparum | null | false | true | 25 | -568.731 | -515.2094 | structures/A0201/KLGVQYFFL |
HLA-A_02_01 | A*02:01 | YVGDNINNV | 9 | IC50 | 1,818 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Cysteine-rich protective antigen | Q8IFM8.1 | Plasmodium falciparum | null | false | true | 25 | -545.84 | -502.8687 | structures/A0201/YVGDNINNV |
HLA-A_02_01 | A*02:01 | YIFFNNENSI | 10 | IC50 | 2,825 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Cysteine-rich protective antigen | Q8IFM8.1 | Plasmodium falciparum | null | false | true | 25 | -548.693 | -455.3474 | structures/A0201/YIFFNNENSI |
HLA-A_02_01 | A*02:01 | KVKDSWITL | 9 | IC50 | 4,009 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Cysteine-rich protective antigen | Q8IFM8.1 | Plasmodium falciparum | null | false | true | 25 | -563.969 | -520.1399 | structures/A0201/KVKDSWITL |
HLA-A_02_01 | A*02:01 | VQYFFLRPYI | 10 | IC50 | 100,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Cysteine-rich protective antigen | Q8IFM8.1 | Plasmodium falciparum | null | false | true | 25 | -537.881 | -439.7014 | structures/A0201/VQYFFLRPYI |
HLA-A_02_01 | A*02:01 | HLNNIFHHL | 9 | IC50 | 225 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -558.424 | -507.732 | structures/A0201/HLNNIFHHL |
HLA-A_02_01 | A*02:01 | VIIPHYTFL | 9 | IC50 | 595 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -560.84 | -532.847 | structures/A0201/VIIPHYTFL |
HLA-A_02_01 | A*02:01 | YIHKLILSV | 9 | IC50 | 1,153 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -555.076 | -487.3812 | structures/A0201/YIHKLILSV |
HLA-A_02_01 | A*02:01 | NIFHHLIYV | 9 | IC50 | 2,285 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -558.32 | -526.5499 | structures/A0201/NIFHHLIYV |
HLA-A_02_01 | A*02:01 | YLNTNVNDGL | 10 | IC50 | 2,834 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -563.993 | -524.4458 | structures/A0201/YLNTNVNDGL |
HLA-A_02_01 | A*02:01 | ILDMSNEYSL | 10 | IC50 | 6,870 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -564.795 | -530.0106 | structures/A0201/ILDMSNEYSL |
HLA-A_02_01 | A*02:01 | SLFITSDHL | 9 | IC50 | 7,121 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -562.97 | -470.5294 | structures/A0201/SLFITSDHL |
HLA-A_02_01 | A*02:01 | KINETYDKV | 9 | IC50 | 10,071 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -539.12 | -494.6982 | structures/A0201/KINETYDKV |
HLA-A_02_01 | A*02:01 | FLQYHFKEL | 9 | IC50 | 14,558 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -548.403 | -519.8237 | structures/A0201/FLQYHFKEL |
HLA-A_02_01 | A*02:01 | FIPSHNSFI | 9 | IC50 | 30,952 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -556.075 | -476.9025 | structures/A0201/FIPSHNSFI |
HLA-A_02_01 | A*02:01 | YIYIDTIKFI | 10 | IC50 | 53,094 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -505.391 | -318.1304 | structures/A0201/YIYIDTIKFI |
HLA-A_02_01 | A*02:01 | RQMLYNTFYS | 10 | IC50 | 319,024 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -575.926 | -533.8198 | structures/A0201/RQMLYNTFYS |
HLA-A_02_01 | A*02:01 | KMMDEYNTKK | 10 | IC50 | 511,314 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -560.472 | -529.1916 | structures/A0201/KMMDEYNTKK |
HLA-A_02_01 | A*02:01 | DMSNEYSLFI | 10 | IC50 | 100,000 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 34,305,923 | Reticulocyte-binding protein homolog 5 | Q8IFM5.1 | Plasmodium falciparum | null | false | true | 25 | -538.971 | -501.3152 | structures/A0201/DMSNEYSLFI |
HLA-A_02_01 | A*02:01 | KTWGQYWQV | 9 | Kd | 1,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Melanocyte protein PMEL | P40967.2 | Homo sapiens | null | false | true | 25 | -561.428 | -524.5102 | structures/A0201/KTWGQYWQV |
HLA-A_02_01 | A*02:01 | AMLGTHTMEV | 10 | Kd | 1,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Melanocyte protein PMEL | P40967.2 | Homo sapiens | null | false | true | 25 | -559.45 | -518.5696 | structures/A0201/AMLGTHTMEV |
HLA-A_02_01 | A*02:01 | ITDQVPFSV | 9 | Kd | 1,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Melanocyte protein PMEL | P40967.2 | Homo sapiens | null | false | true | 25 | -560.614 | -516.5402 | structures/A0201/ITDQVPFSV |
HLA-A_02_01 | A*02:01 | LLMEKEDYHSL | 11 | Kd | 100 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Tyrosinase | P14679.3 | Homo sapiens | null | false | true | 25 | -585.879 | -555.9505 | structures/A0201/LLMEKEDYHSL |
HLA-A_02_01 | A*02:01 | AAGIGILTV | 9 | Kd | 10,000 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Melanoma antigen recognized by T-cells 1 | NP_005502.1 | Homo sapiens | null | false | true | 25 | -557.823 | -501.8248 | structures/A0201/AAGIGILTV |
HLA-A_02_01 | A*02:01 | VLLLWITAA | 9 | IC50 | 11 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 34,471,285 | Probable protein E5 | AAD24028.1 | Human papillomavirus 16 | null | false | true | 25 | -560.872 | -519.0438 | structures/A0201/VLLLWITAA |
HLA-A_02_01 | A*02:01 | HLIDPNTLQV | 10 | Kd | 10 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | 60S ribosomal export protein NMD3 | C9JA08.1 | Homo sapiens | null | false | true | 25 | -574.855 | -480.9784 | structures/A0201/HLIDPNTLQV |
HLA-A_02_01 | A*02:01 | QLPDSVNQL | 9 | Kd | 100 | nM | purified MHC/direct/fluorescence | dissociation constant (KD) | 34,290,406 | Transmembrane protein 214 | Q6NUQ4.2 | Homo sapiens | null | false | true | 25 | -550.552 | -482.9617 | structures/A0201/QLPDSVNQL |
HLA-A_02_01 | A*02:01 | FLTPKKLQCV | 10 | IC50 | 260.4 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 9,457,311 | Prostate-specific antigen | P07288.2 | Homo sapiens | null | false | true | 25 | -536.769 | -474.878 | structures/A0201/FLTPKKLQCV |
HLA-A_02_01 | A*02:01 | VLVHPQWVL | 9 | IC50 | 2,083.3 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 9,457,311 | Prostate-specific antigen | P07288.2 | Homo sapiens | null | false | true | 25 | -556.567 | -509.5791 | structures/A0201/VLVHPQWVL |
HLA-A_02_01 | A*02:01 | KLQCVDLHV | 9 | IC50 | 396.8 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 9,457,311 | Prostate-specific antigen | P07288.2 | Homo sapiens | null | false | true | 25 | -556.183 | -515.1454 | structures/A0201/KLQCVDLHV |
HLA-A_02_01 | A*02:01 | MLLRLSEPA | 9 | IC50 | 657.9 | nM | purified MHC/competitive/fluorescence | half maximal inhibitory concentration (IC50) | 9,457,311 | Prostate-specific antigen | P07288.2 | Homo sapiens | null | false | true | 25 | -562.957 | -522.7769 | structures/A0201/MLLRLSEPA |
HLA-A_02_01 | A*02:01 | GRAKLLGAEEK | 11 | IC50 | 50,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | 7K1H_A | Homo sapiens | null | false | true | 25 | -552.794 | -517.0606 | structures/A0201/GRAKLLGAEEK |
HLA-A_02_01 | A*02:01 | RAKLLGAEEK | 10 | IC50 | 50,000 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,927,123 | Epidermal growth factor receptor | 7K1H_A | Homo sapiens | null | false | true | 25 | -516.468 | -485.2644 | structures/A0201/RAKLLGAEEK |
HLA-A_02_01 | A*02:01 | CQWGRLWQL | 9 | IC50 | 1,425 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 32,571,843 | WD repeat-containing protein 46 | ONTIE_0003248 | Homo sapiens | null | false | true | 25 | -553.911 | -468.7047 | structures/A0201/CQWGRLWQL |
HLA-A_02_01 | A*02:01 | YLQPRTFLL | 9 | Kd | 75 | nM | binding assay | dissociation constant (KD) | 37,796,941 | Spike glycoprotein | P0DTC2.1 | Severe acute respiratory syndrome coronavirus 2 Indonesia/JI-ITD-12202V/2020 | null | false | true | 25 | -574.858 | -535.199 | structures/A0201/YLQPRTFLL |
HLA-A_02_01 | A*02:01 | LLALLSCLTI | 10 | IC50 | 384.6 | nM | purified MHC/competitive/radioactivity | half maximal inhibitory concentration (IC50) | 8,566,090 | Genome polyprotein | I3PLL5.1 | Hepacivirus hominis | null | false | true | 25 | -555.285 | -519.7011 | structures/A0201/LLALLSCLTI |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.